Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPPPA
说明： Competitive and GluN2A-selective NMDA antagonist
别名： LY 257883
化学名： (2R*,4S*)-4-(3-Phosphonopropyl)-2-piperidinecarboxylic acid
生物活性 for PPPA
PPPA is a competitive NMDA receptor antagonist that displays moderate selectivity for NR2A-containing receptors (Ki values are 0.13, 0.47, 1.10 and 3.86 μM for GluN2A, GluN2B, GluN2C and GluN2D subunits respectively).
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
技术数据 for PPPA
| 分子量 | 251.22 |
| 公式 | C9H18NO5P |
| 储存 | Desiccate at RT |
| CAS Number | 113190-92-4 |
| PubChem ID | 90488757 |
| InChI Key | GPFGYOMXVORLFH-RXZNUWRWSA-N |
| Smiles | O=P(CCC[C@@H]1C[C@H]([C@](O)=O)NCC1)(O)O.O=C([C@H]2NCC[C@@H](CCCP(O)(O)=O)C2)O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for PPPA
参考文献 for PPPA
参考文献是支持产品生物活性的出版物。
Benveniste and Mayer (1992) Effect of extracellular pH on the potency of N-MthD.-aspartic acid receptor competitive antagonists. Mol.Pharmacol. 42 679 PMID: 1435743
Feng et al (2005) The effect of competitive antagonist chain length on NMDA receptor subunit selectivity. Neuropharmacology 48 354 PMID: 15721167
Kinarsky et al (2005) Identification of subunit- and antagonist-specific amino acid residues in the N-MthD.-aspartate receptor glutamate-binding pocket. J.Pharmacol.Exp.Ther. 313 1066 PMID: 15743930
按产品操作查看相关产品
关键词: PPPA, PPPA supplier, Competitive, NR2A, antagonists, Glutamate, NMDA, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, LY257883, GluN2A, GluN2B, LY, 257883, 2274, Tocris Bioscience
1 篇 PPPA 的引用文献
引用文献是使用了 Tocris 产品的出版物。 PPPA 的部分引用包括：
Liu et al (2015) The distinct role of NR2B subunit in the enhancement of visual plasticity in adulthood. Mol Brain 8 49 PMID: 26282667
PPPA 的评论
目前没有该产品的评论。 Be the first to review PPPA and earn rewards!
Have you used PPPA?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.